Research Archive
-
March 12, 2020
Clinical investigation society lauds Vanderbilt scientists
Five faculty members of Vanderbilt University School of Medicine are among 80 physician-scientists who will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry. They are: -
February 27, 2020
Study finds certain genetic test not useful in predicting heart disease risk
A Polygenic Risk Score — a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients — has been found not to be a useful predictive biomarker for disease risk. -
February 27, 2020
Breast cancer study may help predict treatment response
Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat. -
February 27, 2020
Grant bolsters research on subjective cognitive decline
Katherine Gifford, PsyD, MS, assistant professor of Neurology, has been awarded a five-year, $4.3 million research grant from the National Institute on Aging to study what subjective cognitive decline can reveal about underlying pathology. -
February 27, 2020
Bordenstein honored by Genetics Society of America
The Genetics Society of America has recognized Seth Bordenstein, PhD, an evolutionary geneticist and microbiologist at Vanderbilt, for an initiative that brings real-world scientific research into middle school, high school and college biology classes. -
February 26, 2020
Potential new heartburn drug studied at VUMC
An investigational drug that binds bile acids in the stomach can reduce the severity of heartburn symptoms in patients with treatment-resistant gastroesophageal reflux disease (GERD) when combined with a proton pump inhibitor (PPI), a new study suggests. -
February 20, 2020
Post-transplant diabetes may be reversible: study
Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report.